BidaskClub Lowers Orthopediatrics (NASDAQ:KIDS) to Buy

BidaskClub cut shares of Orthopediatrics (NASDAQ:KIDS) from a strong-buy rating to a buy rating in a research report report published on Wednesday morning, BidAskClub reports.

Other equities research analysts have also recently issued reports about the stock. BTIG Research increased their target price on shares of Orthopediatrics to $44.00 and gave the company a buy rating in a research report on Friday, March 8th. Zacks Investment Research upgraded shares of Orthopediatrics from a hold rating to a buy rating and set a $46.00 price objective for the company in a research report on Saturday, March 16th. Finally, JMP Securities initiated coverage on shares of Orthopediatrics in a research report on Wednesday, February 20th. They set an outperform rating and a $44.00 price objective for the company. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $41.00.

Shares of NASDAQ KIDS opened at $40.16 on Wednesday. The stock has a market capitalization of $601.65 million, a PE ratio of -41.83 and a beta of 0.23. The company has a quick ratio of 6.01, a current ratio of 8.60 and a debt-to-equity ratio of 0.26. Orthopediatrics has a 52 week low of $25.11 and a 52 week high of $47.82.

Orthopediatrics (NASDAQ:KIDS) last issued its earnings results on Wednesday, May 8th. The company reported ($0.21) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.04). The business had revenue of $14.66 million during the quarter, compared to analyst estimates of $14.67 million. Orthopediatrics had a negative net margin of 16.71% and a negative return on equity of 16.43%. As a group, equities research analysts predict that Orthopediatrics will post -0.45 EPS for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in KIDS. JPMorgan Chase & Co. increased its position in Orthopediatrics by 20.5% during the third quarter. JPMorgan Chase & Co. now owns 70,225 shares of the company’s stock worth $2,573,000 after purchasing an additional 11,931 shares during the last quarter. Vanguard Group Inc. increased its position in Orthopediatrics by 9.6% during the third quarter. Vanguard Group Inc. now owns 319,553 shares of the company’s stock worth $11,708,000 after purchasing an additional 28,073 shares during the last quarter. Bank of Montreal Can increased its position in Orthopediatrics by 4,156.3% during the fourth quarter. Bank of Montreal Can now owns 2,043 shares of the company’s stock worth $71,000 after purchasing an additional 1,995 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new stake in Orthopediatrics during the fourth quarter worth about $168,000. Finally, Rhumbline Advisers increased its position in Orthopediatrics by 55.5% during the fourth quarter. Rhumbline Advisers now owns 8,770 shares of the company’s stock worth $306,000 after purchasing an additional 3,129 shares during the last quarter. Hedge funds and other institutional investors own 48.67% of the company’s stock.

About Orthopediatrics

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Read More: Preferred Stock

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.